385 related articles for article (PubMed ID: 25526608)
21. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
[TBL] [Abstract][Full Text] [Related]
22. Interventions for mycosis fungoides.
Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
[TBL] [Abstract][Full Text] [Related]
23. [Lentigo maligna treated with 5% imiquimod cream].
Martín T; Ojeda A; Martínez S; Vera A
Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
[TBL] [Abstract][Full Text] [Related]
24. Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
Kai AC; Richards T; Coleman A; Mallipeddi R; Barlow R; Craythorne EE
Br J Dermatol; 2016 Jan; 174(1):165-8. PubMed ID: 26595446
[TBL] [Abstract][Full Text] [Related]
25. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
26. Variation in the diagnosis and clinical management of lentigo maligna across Europe: a survey study among European Association of Dermatologists and Venereologists members.
Tio D; Prinsen CAC; Dréno B; Hoekzema R; Augustin M; van Montfrans C
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1476-1484. PubMed ID: 29419913
[TBL] [Abstract][Full Text] [Related]
27. Topical treatments for scalp psoriasis.
Schlager JG; Rosumeck S; Werner RN; Jacobs A; Schmitt J; Schlager C; Nast A
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009687. PubMed ID: 26915340
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
[TBL] [Abstract][Full Text] [Related]
29. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
Powell AM; Robson AM; Russell-Jones R; Barlow RJ
Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
[TBL] [Abstract][Full Text] [Related]
30. Lentigo maligna: a review.
Karponis D; Stratigos IA; Joshy J; Craig PJ; Mistry K; van Bodegraven B; Venables ZC; Levell NJ
Clin Exp Dermatol; 2024 Feb; 49(3):218-225. PubMed ID: 37966718
[TBL] [Abstract][Full Text] [Related]
31. Topical imiquimod therapy for lentigo maligna.
Mahoney MH; Joseph MG; Temple C
Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
[TBL] [Abstract][Full Text] [Related]
32. Interventions for infantile haemangiomas of the skin.
Novoa M; Baselga E; Beltran S; Giraldo L; Shahbaz A; Pardo-Hernandez H; Arevalo-Rodriguez I
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD006545. PubMed ID: 29667726
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of non-surgical treatments for lentigo maligna.
Read T; Noonan C; David M; Wagels M; Foote M; Schaider H; Soyer HP; Smithers BM
J Eur Acad Dermatol Venereol; 2016 May; 30(5):748-53. PubMed ID: 26299846
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
[TBL] [Abstract][Full Text] [Related]
36. Series of Fourteen Cases of Topical Imiquimod 5% in Lentigo Maligna: Treatment Modalities and Clues for Detecting Recurrences.
Poveda-Montoyo I; Álvarez-Chinchilla P; Schneller-Pavelescu L; Hispán-Ocete P; Bañuls-Roca J
Actas Dermosifiliogr; 2022 Apr; 113(4):T407-T412. PubMed ID: 35623739
[TBL] [Abstract][Full Text] [Related]
37. Lentigo maligna: current concepts in diagnosis and management.
Walling HW
G Ital Dermatol Venereol; 2009 Apr; 144(2):149-55. PubMed ID: 19357622
[TBL] [Abstract][Full Text] [Related]
38. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
Spenny ML; Walford J; Werchniak AE; Beltrani V; Brennick JB; Storm CA; Perry AE; Chapman MS
Cutis; 2007 Feb; 79(2):149-52. PubMed ID: 17388218
[TBL] [Abstract][Full Text] [Related]
39. Interventions for Old World cutaneous leishmaniasis.
Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005067. PubMed ID: 29192424
[TBL] [Abstract][Full Text] [Related]
40. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study.
Marsden JR; Fox R; Boota NM; Cook M; Wheatley K; Billingham LJ; Steven NM;
Br J Dermatol; 2017 May; 176(5):1148-1154. PubMed ID: 27714781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
